Ocugen Inc. (NASDAQ: OCGN) stock declined by 2.13% at the last trading close whereas the OCGN stock price rises by 16.30% in the pre-market trading. Ocugen, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of gene therapy to treat blindness and the development of a COVID-19 vaccine.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
What is happening?
On April 20, 2021, it was being announced that Bharat Biotech initially developed a coronavirus vaccine, which Ocugen would soon co-develop and produce. Given the enormous need for such vaccinations around the world, the deal’s near-term sales prospects may be enormous. It’s true that there’s plenty of demand for more coronavirus vaccines on the market, but the facts matter.
Bharat Biotech, a co-development partner, on 21, April 2021 reported promising findings from the second interim review of COVAXIN, a whole virion inactivated COVID-19 vaccine candidate, in its Phase 3 trial, but it has yet to be approved by the US Food and Drug Administration. That’s a challenge because Ocugen’s commercialization agreement only applies to the United States, where vaccination is moving ahead of time with vaccines that have already been approved for sale.
As a result, the sales capacity is expected to be lower than Reddit traders had anticipated.COVAXIN had a 78 percent efficacy against mild, moderate, and serious COVID-19 disease, with a 100 percent efficacy against severe COVID-19 disease alone.
Also,
The reality is that the OCGN can only receive 45 percent of the revenues from Covaxin purchases in the United States. Ocugen is a biotech company in the early stages with no clinical trials underway; it is not a pharmaceutical company. In other words, it has no track record of profitably producing something, let alone a commodity created by anyone else. It doesn’t mean it’ll crash, but it does mean that investors should be aware that it’s a much riskier bet than it seems on the surface.
